GEMINI trial
Sanofi’s MS Drug Tolebrutinib Faces FDA Delay Amid Extended Review
Sanofi; tolebrutinib; FDA delay; multiple sclerosis; nrSPMS; Bruton’s tyrosine kinase inhibitor; breakthrough therapy; HERCULES trial; GEMINI trial; PERSEUS trial; NDA; regulatory review